Table 4

Performance of the Eversense and FSL with FSLCstrip according to ICGMA guidelines, using FSLCstrip as reference

Exercise
(n=908)
Normal daily activity (n=814)ICGMA: lower bound of one-sided
95% CI
Eversense
Hypoglycemia (<70 mg/dL)72% (44/61)76% (37/49)>85% within ±15 mg/dL
97% (59/61)90% (44/49)>98% within ±40 mg/dL
Euglycemia (70–180 mg/dL)56% (307/544)69% (345/504)>70% within ±15%
92% (498/544)96% (486/504)>99% within ±40%
Hyperglycemia (>180 mg/dL)68% (205/303)75% (195/261)>80% within ±15%
95% (287/303)98% (256/261)>99% within ±40%
Overall69% (537/908)
59% (628/908)
70% (565/814)
81% (655/814)
Within ±15%
>87% within ±20%
FSL
Hypoglycemia (<70 mg/dL)61% (37/61)78% (38/49)>85% within ±15 mg/dL
92% (56/61)100% (49/49)>98% within ±40 mg/dL
Euglycemia (70–180 mg/dL)47% (255/544)67% (337/504)>70% within ±15%
90% (490/544)96% (483/504)>99% within ±40%
Hyperglycemia (>180 mg/dL)47% (142/303)81% (212/261)>80% within ±15%
90% (273/303)99% (258/261)>99% within ±40%
Overall46% (420/908)
59% (533/908)
71% (575/908
83% (672/814)
Within ±15%
>87% within ±20%
  • FSL, Free Style Libre; FSLCstrip, Free Style Libre Precision NeoPro strip; ICGMA, Integrated Continuous Glucose Monitoring Approvals (class II–510(K) guidelines).